Thalidomide BMS (previously Thalidomide Celgene)
What Thalidomide BMS (previously Thalidomide Celgene) is used for
Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Thalidomide BMS (previously Thalidomide Celgene)
- Active substance
- thalidomide
- Disease area
- Multiple Myeloma
- Medicine group
- Immunosuppressants
- ATC code
- L04AX02
- Marketing authorisation holder
- Bristol-Myers Squibb Pharma EEIG
- Authorised in the EU since
- 2008
Official information
In India
- Thalidomide: 31 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Thalidomide BMS (previously Thalidomide Celgene) used for?
Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).
What is the active substance in Thalidomide BMS (previously Thalidomide Celgene)?
Thalidomide BMS (previously Thalidomide Celgene) contains thalidomide.
Who makes Thalidomide BMS (previously Thalidomide Celgene)?
The EU marketing authorisation holder is Bristol-Myers Squibb Pharma EEIG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU